These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23515325)

  • 21. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Townsend CM; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Tsoulis DJ; MacDonald JK
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A home infliximab infusion program.
    Condino AA; Fidanza S; Hoffenberg EJ
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T; Rawlins M; Kozarek R; France R; Patterson D
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.
    Viola A; Costantino G; Privitera AC; Bossa F; Lauria A; Grossi L; Principi MB; Della Valle N; Cappello M
    World J Gastrointest Pharmacol Ther; 2017 May; 8(2):131-136. PubMed ID: 28533923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
    Checkley LA; Kristofek L; Kile S; Bolgar W
    Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P013 Resolution of Infliximab Associated Infusion Hypersensitivity After Switching to Biosimilar Infliximab-dyyb.
    Irani M; Bryant R; Lofton H; Abraham B
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S3. PubMed ID: 37461933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.
    Armuzzi A; Fiorino G; Variola A; Manetti N; Fries W; Orlando A; Maconi G; Bossa F; Cappello M; Biancone L; Cantoro L; Costa F; D'Incà R; Lionetti P; Principi M; Castiglione F; Annunziata ML; Di Sabatino A; Di Girolamo M; Terpin MM; Cortelezzi CC; Saibeni S; Amato A; Ardizzone S; Guidi L; Danese S; Massella A; Ventra A; Rizzuto G; Massari A; Perri F; Annese V;
    Inflamm Bowel Dis; 2019 Feb; 25(3):568-579. PubMed ID: 30137352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence and management of infusion reactions to infliximab: a large center experience.
    Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
    Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.